Abstract
Maraviroc, a CCR5 antagonist, is effective in treatment-experienced patients with R5-tropic HIV (JW AIDS Clin Care Sep 10 2007). In a manufacturer-funded trial, researchers assessed maraviroc’s safety and efficacy in patients with dual- or mixed-tropic virus (simply called “non-R5 virus”), viral loads ≥5000 copies/mL, and documented resistance to at least two classes of antiretroviral therapy (ART) or at …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
